Baxter Receives FDA Approval for Advate 4000 IU
- By BSTQ Staff
Baxter International has received U.S. Food and Drug Administration (FDA) approval for a 4,000 IU dosage of Advate (Antihemophilic Factor [Recombinant], Plasma/Albumin-Free Method). Advate is meant for the avoidance or curtailment of bleeding in victims of hemophilia A. The latest 4,000 IU dose provides the ease of a single dosage for many patients.
Last December, Advate received FDA approval as a regular prophylaxis to curtail the incidence of bleeding for patients with hemophilia A. It thus became the sole antihemophilic recombinant FVIII therapy approved in the domestic market for use by both children and adults.
